Partial opioid receptor agonists

Tonazocine is a partial opioid receptor agonist that has not been reported to have adverse effects on the cardiovascular system or to cause clinically significant respiratory depression. When single doses of tonazocine 2,4, and 8 mg were compared in 150 adults postoperatively. 

It is a potent and long acting opioid with partial mu receptor agonist property. 25 times more potent than morphine. Effects are similar to morphine but constipation is less marked. It undergoes extensive presystemic elimination and therefore is... 

The concurrent administration of methadone to heroin addicts known to be recidivists has been questioned because of the increased risk of overdose death secondary to respiratory arrest. Buprenorphine, a partial M-receptor agonist with long-acting properties, has been found to be effective in opioid detoxification and maintenance programs and is presumably associated with a lower risk of such overdose fatalities. 

Pentasa mesalazine. pentazocine [ban,inn.jan,usan] (pentazocine hydrochloride [usan] pentazocine lactate [usan] NSC 107430 Fortagesic Fortral Talwin ) is one of the benzomorphan series and is a (mixed partial p and full k) OPIOID RECEPTOR AGONIST with OPIOID ANALGESIC activity. It is used orally or by injection to treat moderate to severe pain, pentazocine hydrochloride pentazocine, pentazocine lactate pentazocine, pentetrazol [ban, inn] (pentylenetetrazole pentamethylenetetrazole) has similar properties to doxapram as a CNS stimulant and respiratory stimulant. It was previously used intramuscularly to treat barbiturate and other CNS depressants in overdose, and orally for bronchial disorders. 

Tramake Tramal Zydol ) is a phenylcyclohexanol derivative, a (p) OPIOID RECEPTOR agonist with partial OPIOID ANALGESIC activity. It is also a monoamine (serotonin and noradrenaline) re-UPTAKE inhibitor, and this mechanism is thought independently to contribute a component to analgesic activity. 

Although morphine is a classical p opioid receptor agonist, its intrinsic activity is known to be lower than that of a representative full p opioid receptor agonist, DAMGO. Moreover, recent reports showed that morphine was a partial agonist for the opioid p receptor in some pharmacological assays. See [34-38]. 

Woody GE, Luborsky L, McLellan AT, et al Psychotherapy for opiate addicts does it help Arch Gen Psychiatry 40 639—645, 1983 Woody GE, McLellan AT, Luborsky L, et al Severity of psychiatric symptoms as a predictor of benefits from psychotherapy the Veterans Administration-Penn study. Am J Psychiatry 141 1172—1177, 1984 Woody GE, McLellan AT, Luborsky L, et al Twelve-month follow-up of psychotherapy for opiate dependence. Am J Psychiatry 144 590-596, 1987 Yabaluri N, Medzihradsky F Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling. Mol Pharmacol 52 896-902, 1997... 

Bot G, Blake A, Li S, Reisine T. Mutagenesis of a single amino acid in the rat mu opioid receptor discriminates the binding of full agonists from partial agonists and antagonists. J Neurochem 1998 70 358-365. 

Bot, G, Blake, A, Li, S, Reisine, T. Mutagenesis of the mouse delta opioid receptor converts - buprenorphine from a partial agonist to an antagonist. J Pharmacol Exp Ther 1998 284 283-290. 

The answer is c. (Hardman, p 546.) Pentazocine is a mixed agonist-antagonist of opioid receptors. When a partial agonist, such as pentazocine, displaces a full agonist, such as methadone, the receptor is less activated this leads to withdrawal syndrome in an opioid-dependent person. 

Partial agonists and antagonists compete with agonists for opioid receptor sites and exhibit mixed agonist-antagonist activity. They may have selectivity for analgesic receptor sites and cause fewer side effects. 

In October 2002, the FDA approved two new medications for treating opiate addiction, both developed by Reckitt Benckiser Pharmaceuticals. The new drugs, Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) contain buprenorphine, a partial opioid agonist. Like methadone, buprenorphine binds to the brain s opioid receptors, but produces significantly reduced pleasurable effects than heroin. 

FDA approved October 8, 2002 Receptor blocker (partial opioid agonist)... 

The antagonist action of partial agonists may result in an initial decrease in effect of a full agonist during changeover to the latter. Intoxication with buprenorphine cannot be reversed with antagonists, because the drug dissociates only very slowly from the opioid receptors and competitive occupancy of the receptors cannot be achieved as fast as the clinical situation demands. 

Table 2. Agonists, antagonists and partial agonists for the various opioid receptors...

---